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Abstract
Background: Combination of different agents is widely used in clinic to combat complex diseases with improved
therapy and reduced side effects. However, the identification of effective drug combinations remains a challenging
task due to the huge number of possible combinations among candidate drugs that makes it impractical to screen
putative combinations.
Results: In this work, we construct a ‘drug cocktail network’ using all the known effective drug combinations
extracted from the Drug Combination Database (DCDB), and propose a network-based approach to investigate
drug combinations. Our results show that the agents in an effective combination tend to have more similar
therapeutic effects and share more interaction partners. Based on our observations, we further develop a statistical
approach termed as DCPred (Drug Combination Predictor) to predict possible drug combinations by exploiting the
topological features of the drug cocktail network. Validating on the known drug combinations, DCPred achieves
the overall AUC (Area Under the receiver operating characteristic Curve) score of 0.92, indicating the predictive
power of our proposed approach.
Conclusions: The drug cocktail network constructed in this work provides useful insights into the underlying rules
of effective drug combinations and offer important clues to accelerate the future discovery of new drug
combinations.
Background
Drug combination is the combination of different agents
that can achieve better efficacy with less side effects
compared to its single components. Recently, it is
becoming a popular and promising strategy to new drug
discovery, especially for treating complex diseases, e.g.
cancer [1-3]. For example, Moduretic is the combination
of Amiloride and Hydrochlorothiazide, which is an
approved combination used to treat patients with hyper-
tension [4,5]. Chan et al. identified a combination drug,
namely Tri-Luma, for combating melasma (dark skin
patches) of the face based on efficacy and safety experi-
ments [6]. Agrawal et al. found two effective combina-
torial drug regimens to treat Huntington disease based
on prescreening in Drosophila [7]. In addition, through
the synergistic antiangiogenic effects, very low-dose
combinatorial use of vinblastine (VBL) and rapamycin
(RAP) was demonstrated to inhibit the proliferation of
the endothelial cells much more effectively than single
drug treatment both in vitro and in vivo [8]. Recently,
Lehar et al. found that synergistic drug combinations
may have less side effects, because synergistic drug com-
binations are generally more selective to particular cellu-
lar contexts than single agents, and the dosage of each
compound in combination will be reduced compara-
tively [9]. Despite of the extensive efforts that have been
made to discover new drug combinations in the past
few decades, the majority of effective combinatorial
drugs used in clinic were discovered through experi-
ences, which generally require labor-intensive and time-
consuming “brute force” screening of all possible combi-
nations among the approved individual drugs [10]. In a
drug combination, a drug may promote or suppress the
effect of another one. For instance, cyclosporine
increases the effect of sirolimus, while bupropion
decreases the effect of cyclosporine. As a result, two
drugs may have a totally new effect that is different
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from the ones of either individual drugs [11,12]. Accord-
ingly, the presence of potential drug-drug interactions
(DDIs) and the possibility of pharmacokinetic interven-
tions between the drugs could confound the identifica-
tion of effective drug combinations [13]. Furthermore,
the number of possible combinations will increase expo-
nentially with the increasing availability of single drugs.
For example, in the case of four drugs, there will be six
possible combinations. This number would be enormous
considering the fact that there are thousands of
approved drugs. Due to the huge search space of possi-
ble combinations between known drugs, the identifica-
tion of optimal and effective drug combinations is a
non-trivial and challenging task.
Therefore, it is necessary to develop effective in silico
methods that are capable of discovering new drug com-
binations prior to combination synthesis and practical
test in the lab. Owing to the completion of human gen-
ome sequencing projects and the advancement of mole-
cular medicine, extensive system biology efforts have
been made to discover new combinations based on
molecular interaction networks [14,15] in the past few
years [16-19]. Nevertheless, there is still a long way to
go before we reach the stage of devising generally
applicable and effective prediction models. Recently,
there have been considerable progresses in developing
new approaches for identifying drug-drug interactions
and even drug combinations [13]. In this context, Geva-
Zatorsky et al. have recently found that the protein
dynamics in response to drug combination can be accu-
rately described by a linear superposition of the
dynamics under the corresponding individual drugs [16].
Their study indicated that protein dynamics of three-
and four-drug combinations can be predicted based on
the drug combination pairs, thereby providing a useful
way for reducing the search space of possible drug com-
binations. Calzolari et al. devised an efficient search
algorithm originated from information theory for opti-
mization of drug combinations based on the sequential
decoding algorithms [17]. More recently, researchers
have also developed computational frameworks for pre-
dicting drug combinations and synergistic effects based
on high-throughput data [18-20].
In this work, we study the drug combinations in terms
of their therapeutic similarity and the network topology
of a drug cocktail network constructed from the effec-
tive drug combinations deposited in the Drug Combina-
tion Database (DCDB) [21]. We find that the drugs in
an effective combination tend to have more similar ther-
apeutic effects and share more interaction partners in
the context of drug cocktail network. We further
develop a statistical approach called DCPred to predict
possible drug combinations and validate this approach
based on a benchmark dataset with all the known
effective drug combinations. As a result, DCPred
achieves the overall best AUC (Area Under the receiver
operating characteristic Curve) score of 0.92, demon-
strating the predictive capability of the proposed
approach and its potential value in identifying new pos-
sible drug combinations.
Results and discussion
The drug cocktail network
In this study, we extracted 239 known effective pairwise
drug combinations from DCDB [21]. The information of
ATC code for each drug was obtained from DrugBank
[22]. Based on these datasets, we constructed a drug
cocktail network with 215 nodes and 239 edges (see Fig-
ure 1 for the visualization of this network), where nodes
represent the drugs and an edge is connected if two
drugs are found in an effective drug combination. Build-
ing up this network can thus give the readers a visual
impression of the relationships between drugs that can
form effective combinations. Moreover, the network the-
ory can be utilized to explore possible combinatorial
mechanisms between drugs. In Figure 1, the size of each
node approximates its degree, and the width of each
edge approximates the therapeutic similarity (TS) (as
defined in Equation 3) between the two drugs linked by
the edge, while the grey edges indicate that the two
drugs linked by the edge have totally different therapeu-
tical effects. In addition, we found 102 drugs that have
at least two neighbors in the drug cocktail network,
which we termed as “star drugs” hereafter and 91 of
which have target protein annotations in DrugBank.
Since most of biological networks are scale-free net-
works [23], we analyzed the topology of the drug cocktail
network in order to find out whether it is also a scale-
free network. The degree distribution of the drug cocktail
network is shown in Figure 2. It is evident that the degree
distribution follows a power law distribution, suggesting
that it is indeed a scale-free network. That is, the fraction
P(x) of nodes in the drug cocktail network having x con-
nections to other nodes can be described as:
p(x) ∝ cx−α (1)
where c = 2.1 and a = 1.9 in this case.
As the drug cocktail network shown in Figure 1 is not
fully connected, the top 6 largest subnetworks were cho-
sen for further analysis. We considered the drug cocktail
network as the union of these 6 subnetworks hereafter
unless stated specifically. In particular, each subnetwork
was found to be enriched for one or several therapeutic
classes according to the ATC classification system, as
shown in Table 1. In other words, the drugs having
similar therapeutic effects tend to be clustered together
in the drug cocktail network.
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Figure 1 The drug cocktail network. A node represents a drug and an edge denotes an effective combination consisting of the two drugs
linked by the edge. The hub drugs that have more than 6 neighbors are colored in red. The size of each node approximates its degree, the
width of each edge approximates the therapeutic similarity (see equation 3) between the two drugs linked by the edge, and a grey edge means
that the two drugs linked by that edge have completely different therapeutic effects. The numbers in panel 1-6 represent the top six largest
child networks from the drug cocktail network.
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To test our hypothesis that the drugs in one combina-
tion tend to have similar therapeutic effects, the drug
cocktail network was compared against random combi-
nation networks. For this purpose, a therapeutic similar-
ity (TS) score was calculated for each drug pair, and the
average of all TS scores was used as the TS score for
the whole drug cocktail network. The random combina-
tion networks were generated by randomly shuffling the
edges while still preserving the degree for each node
[24] in the drug cocktail network. This procedure was
repeated for 1,000 times. To examine the statistical sig-
nificance of the difference between the drug cocktail
network and random combination networks, one P-
value was calculated as the ratio that the TSs of random
combination networks are larger than that of the drug
cocktail network during the 1000 randomizations. The
results are shown in Table 2 at different ATC code
levels ranging from 1 to 4. The calculated P-values of
the drug cocktail network across ATC code levels 1-4
are all equal to 0, strongly suggesting that the real drug
combinations significantly differ from the random com-
bination networks. Note that the 5th ATC code level
was not considered here, as there is only one drug com-
bination having identical ATC codes for all the five
levels in the drug cocktail network. This means that the
5th ATC code level is not suitable for performing statis-
tical analysis and thus it is not included in the analysis.
Furthermore, we studied the therapeutic effects for the
“star drugs” and their neighbors in the drug cocktail
network in order to reveal whether the star drugs have
therapeutic similarities to all their neighbors. Figure 3
shows the distribution of the TS scores for star drugs
and their neighbors. For the effective combination pairs
involving star drugs, 82% have therapeutic similarity,
and most of the star drugs have similar therapeutic
effects as the majority of their neighbors. In contrast,
78% of the combination pairs in the random network do
not have any therapeutic similarity. These results sug-
gest that one star drug tends to be used in combination
Figure 2 The degree distribution of the drug cocktail network. The x-axis represents the common logarithm of the value of degree k, while
the y-axis represents the common logarithm of the fraction of drugs that have the degree of k.
Table 1 The enriched ATC codes for child networks
Subnetwork Number of drugs Enriched ATC codes: Frequency
1 84 L:40, J:24, A:16, S:11
2 29 C:28




The enriched therapeutic effects represented by the ATC codes (first level) for
the top six largest child networks, where the numbering for each child
network is consistent with that shown in Figure 1. Here, the enriched ATC
codes mean that they occur more frequently, either more than 10 times or
accounting for more than 40% of all ATC codes assigned to the drugs in the
child networks.
Table 2 The comparisons between drug cocktail network
and random networks
ATC code level 1 2 3 4
P-value 0/1000 0/1000 0/1000 0/1000
The P-value at which the ratio of the therapeutic similarity (TS) score of a
random network is larger than that of the drug cocktail network in the
randomization tests of 1000 times at different ATC code levels.
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with drugs that have similar therapeutic effects as the
star drug.
Moreover, we also investigated the distribution of
neighbor drug pairs of star drugs (Figure 4A and 4B),
attempting to answer whether or not the drug pairs that
share a star drug have therapeutic similarity. To address
this, we divided the neighbor drug pairs of a star drug
into two groups, according to whether they have similar
ATC codes, or whether they are approved effective com-
binations. We then calculated the percentage of effective
combinations among drug pairs that share a star drug
and have a TS score equal to or larger than a certain
threshold (Figure 4C). From Figure 4C, we can see that
the more similar therapeutic effects (as reflected by the
TS score) two drugs have, the more likely they are effec-
tive combinations. Another important observation is
that the combinations between drugs sharing similar
therapeutic effects and star drugs are more likely effec-
tive combinations.
In various networks, the hub nodes are generally con-
sidered to play important roles [25]. Therefore, we next
studied the 14 hub drugs in the drug cocktail network,
all of which have more than 6 neighbor drugs. The lar-
gest two hub drugs are DB00999 (Hydrochlorothiazide)
and DB00072 (Trastuzumab). Hydrochlorothiazide is
used to treat high blood pressure and edema [26,27].
According to the annotations in DrugBank and DCDB,
we found that all the 18 drug neighbors of hydrochlor-
othiazide can be used to cure hypertension while all the
drug combinations involving hydrochlorothiazide have
been used to treat hypertension. Among these 18
combinations, 11 combinatorial drugs target different
but related pathways while the other 7 ones target unre-
lated pathways (Additional file 1). In the case of Trastu-
zumab used to treat HER2-positive metatsatic breast
cancer [28,29], 5 of its 10 neighbor drugs are used to
treat breast cancer, while the other 5 have pesticide
effects on neoplasm or other cancers. All the 10 drug
combinations are used to treat breast cancer except the
one used for treating gastric cancer. Additionally, 8 drug
combinations target related pathways, while the other
two target different unrelated pathways or cross-talking
pathways (Additional file 2). Finally, these results,
together with the consistent findings shown in Figure 3,
strongly indicate that star drugs tend to have similar
therapeutic characteristics as their neighbors.
In addition, we investigated the proteins targeted by
the 13 hub drugs in the drug cocktail network that have
target information. By mapping all proteins targeted by
the drugs in the drug cocktail network to the human
protein-protein interaction network retrieved from
STRING database [30], we found that, in terms of the
shortest distance between target proteins, hub drugs
tend to have a closer relationship with their combina-
tion partners than the drugs having similar ATC codes
(see Figure 5A). Furthermore, we analyzed the cellular
localizations of these target proteins of the 13 hub drugs
(see Figure 5B). More than 70% of the target proteins of
the hub drugs are membrane proteins, which is reason-
able considering that membrane proteins are widely
involved in various biological processes and represent
the largest class of drug targets.
Figure 3 The distribution of the TS scores between star drugs and their neighbors. Blue and red lines represent the drug cocktail network
and random network, respectively.
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Implication of drug cocktail network for possible drug
combinations
As shown in Figure 3, 82% of the combinations between
star drugs and their neighbors have therapeutic similar-
ity, and most of the star drugs have therapeutic similar-
ity to the majority of their neighbors in the drug
cocktail network. Additionally, most of the effective
combinations are observed to be located in the vicinity
of drug pairs with similar ATC codes. Hence, it is possi-
ble to predict drug combinations from the set of drug
pairs with similar ATC codes. Nonetheless, we found
that there are only 74 known effective combinations in
all of the 1181 possible combinations with similar ATC
codes. Since the number of effective drug combinations
is considerably smaller than that of random combina-
tions between drugs having similar ATC codes, it is a
challenging but crucial task to discover the effective
combinations from the pool with a vast number of ran-
dom combinations.
In Figure 4B and 4C, we can see that if two drugs
with similar ATC codes have a common neighbor in the
drug cocktail network, they are more likely to be com-
bined together. Therefore, we assume that the two
drugs having similar ATC codes and sharing a signifi-
cantly larger number of common partners in the drug
cocktail network are more likely to be combined effec-
tively. Based on this assumption, we further developed a
new statistical approach called DCPred to test this
hypothesis and applied it to predict and rank all the
possible drug combinations (See Materials and methods
for more details). In particular, three different versions
of DCPred were considered in this work, including
Figure 4 Star drugs and their neighbors. (A) The distribution of neighbor drug pairs of star drugs. The neighbor pairs of star drugs can be
classified into two groups, according to whether they have similar ATC codes, or whether they are used as effective combinations. (B) Schematic
view of the relationship between two neighbors d1 and d2 of a star drug. (C) The percentage of effective combinations within neighbor drug
pairs with TS equal to or larger than a certain threshold. Blue and red lines represent the drug cocktail network and the average of 1000
randomly generated combination networks, respectively.
Xu et al. BMC Systems Biology 2012, 6(Suppl 1):S5
http://www.biomedcentral.com/1752-0509/6/S1/S5
Page 6 of 12
DCPred1 considering TS only, DCPred2 considering TS
and drugs with at least 2 neighbors, and DCPred3 con-
sidering TS and drugs with at least 3 neighbors. In the
case of DCPred2 and DCPred3, all possible drug combi-
nations were ranked in ascending order according to the
p-value by equation (4), and the top ones were consid-
ered as putative effective drug combinations. While in
the case of DCPred1, all possible drug combinations
were ranked in descending order according to the TS
value by equation (3), and the top ones were considered
as putative effective drug combinations. The ranking list
of drug combinations can be found in the additional
files (Additional file 3 and 4). We found that two drugs
with more common neighbors generally have higher
rankings. Using the set of 74 effective combinations as
the gold standard while the 1107 random ones as nega-
tive set (Additional file 3), we evaluated our approach in
identifying new drug combinations. Figure 6 shows the
ROC curves [31] obtained by different methods, where
the drug pairs ranked above a given threshold were pre-
dicted as effective drug combinations (positives), while
the rest were regarded as negatives. We then calculated
Figure 5 Target proteins of hub drugs. (A) The blue line represents the shortest distances between the targets of hub drugs and the targets
of their combination partners, while the red line represents the shortest distances between the targets of hub drugs and the targets of drugs
that are therapeutically similar to hub drugs. (B) The distribution of cellular localizations of the target proteins of hub drugs.
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the area under the ROC curves (AUC) [32] for these dif-
ferent DCPred models. As a result, DCPred2 achieved
an AUC score of 0.88 (the green curve in Figure 6), in
comparison with the AUC of 0.75 for the TS-based
method (DCPred1) (the red curve in Figure 6). To com-
prehensively evaluate the predictive power of the three
models, we also calculated three other performance
indexes: Sensitivity, Specificity and Accuracy at varying
thresholds for DCPred1, DCPred2 and DCPred3 models
(See the Additional file 5, 6 and 7, respectively).
Of the top 35 ranked drug combinations inferred by our
models, 63% of them (22/35) are known effective drug
combinations according to DCDB, and 37% (13/35) do
not have any annotations in DCDB (Table 3). Neverthe-
less, 4 out of these 13 drug combinations were reported
in the literature, i.e. the 13th, 22th, 34th and 35th in the
ranking list (Table 3). The 34th ranked one is a combi-
nation of irinotecan and capecitabine, known as XELIRI,
and used to treat metastatic colorectal cancer [33].
Alfonso et al. demonstrated that XELIRI is effective and
safe as the first-line chemotherapy for treating advanced
colorectal cancer or metastatic colorectal cancer [34].
The 13th ranked one is the combination of docetaxel
and gemcitabine, the former interferes with the normal
function of microtubule growth and destroys the cell’s
ability to use its cytoskeleton in a flexible manner, while
the latter inhibits thymidylate synthetase leading to
inhibition of DNA synthesis and cell death [35,36]. Levy
et al. found that gemcitabine-docetaxel combination has
a favorable risk-benefit profile and is an important new
treatment option for women with metastatic breast can-
cer [37]. The 22th one is the combination of sorafenib
and bevacizumab. The former interacts with multiple
intracellular (CRAF, BRAF and mutant BRAF) and cell
surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and
PDGFR-ß) to reduce blood flow to the tumor for the
treatment of patients with advanced renal cell carcinoma
[38], while the latter binds VEGF and prevents the inter-
action of VEGF to its receptors (Flt-1 and KDR) on the
surface of endothelial cells [39]. Consequently, this pre-
vents blood vessel proliferation and tumor metastasis
for metastatic colorectal cancer and HER2-negative
metastatic breast cancer. Azad et al. demonstrated that
complementary inhibition of VEGF signaling has syner-
gistic therapeutic effects, and this combination therapy
has promising clinical activity over ovarian cancer [40].
The 35th one is the combination of thalidomide and
lenalidomide. Thalidomide has been successfully intro-
duced to treat multiple myeloma and its analogue, lena-
lidomide, is also effective in relapsed refractory
myeloma [41]. The Thalidomide-lenalidomide combina-
tion can induce tumour cell apoptosis directly or indir-
ectly by altering bone marrow microenvironment, and
can be used in combination to treat multiple myeloma
Figure 6 The ROC curves of different DCPred models. DCPred1 uses TS only, DCPred2 uses TS and drugs with at least 2 neighbors, while
DCPred3 uses TS and drugs with at least 3 neighbors, respectively.
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[42]. Both drugs bind to a common target PTGS2,
which may play a role as a major mediator of inflamma-
tion and/or a role for prostanoid signaling in activity-
dependent plasticity [43]. Thalidomide and lenalidomide
have been shown to significantly improve the overall
and disease-free survival. Combination of these two
drugs has recently emerged as a promising combination
strategy to improve the patient outcome and drug toxi-
city, especially in the treatment of multiple myeloma
(MM) and hematologic cancers [44].
If we only considered the combinations whose drug
components have at least 3 neighbors, termed as
DCPred3 (the blue curve in Figure 6), we predicted 40
combinations and 379 negative ones (Additional file 4).
DCPred3 achieves an AUC score of 0.92. Compared
with the aforementioned two models DCPred1 and
DCPred2, based on the information of at least 3 neighor
drugs, DCPred3 leads to the overall best performance.
In this work, we considered the results by DCPred2 as
the final results because only few drugs have more than
two neighbors in the drug cocktail network. We hope
that the DCPred models developed in this study can be
used to facilitate the in silico identification of effective
drug combinations and speed up the future discovery
process.
Conclusions
Drug combination is a promising strategy for combating
complex disease, but our complete understanding of the
underlying mechanisms of drug combination is largely
lacking at present. It is therefore imperative to develop
efficient computational methods to infer effective drug
combinations in order to reduce the labor-intensive, time
consuming trial-and-error experiments. In this article, we
extracted all the known effective drug combinations from
DCDB and constructed a drug cocktail network, which
includes 215 drugs and 239 effective drug combinations.
Based on this cocktail network, we observed that the star
drugs tend to have therapeutic similarity with their drug
neighbors, and two drugs having similar therapy and
sharing neighbors tend to be employed in drug combina-
tion. Our analysis also revealed that: 1) hub drugs usually
have similar and even the same therapeutic effects as
their neighbors; 2) target proteins of the hub drugs are
often membrane or membrane-associated proteins; 3) the
components in effective drug combinations usually have
more similar therapeutic effects, making the drug cocktail
network significantly different from the random combi-
nation networks.
From the above observations, we consequently devel-
oped a new statistical approach to infer and rank
Table 3 The novel predictions of DCPred2










































Novel predictions (not reported in DCDB) in the top 35 ranked drug combinations, where only drugs having at least 2 neighbors were included, resulting in 74
positive drug combinations and 1107 random ones.
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possible effective drug combinations by taking into
account drugs with at least two or three drug neighbors.
As a result, our DCPred2 and DCPred3 models achieved
the AUC scores of 0.88 and 0.92, respectively, demon-
strating a good performance. We further applied these
models to rank all the possible drug combinations and
found that the top ranked combinations are more likely
to be effective combinations, according to the cross-
reference to the literature or the similarity of their ATC
codes. In particular, four combinations in the top 35
rankings have been verified as effective combinations by
the literature search. We also show that there is a better
chance for another 3 combinations to be effective com-
binations in terms of the pharmacological similarity.
Our results in this study provide useful insights into the
underlying mechanisms of effective drug combinations
and hence important clues for efficiently reducing the
search space of possible combinations within the
approved drugs. Our approach may be further useful for
developing more accurate models. The DCPred models
are anticipated to be applied to screen more effective
drug combinations with clinical importance.
Furthermore, the concentration of each drug in a
combination is a crucial factor in the study of drug
combination. However, it is currently difficult to utilize
the dosage information of drugs without the knowledge
of their quantitative dose-response profiles (e.g. drug
induced gene/protein expression data) under different
drug concentrations, due to the limited availability of
such data. We will investigate drug combinations from
this perspective in the future, when more data regarding
drug concentrations become available.
Methods
Data sources
The annotations of drug combinations were retrieved
from a newly released Drug Combination Database
(DCDB) [21]. This is a major resource for collecting
effective drug combinations from the literature. The tar-
get protein information, the Anatomical Therapeutic
Chemical (ATC) code annotation of the drugs and pro-
tein subcellular localizations, were extracted from Drug-
Bank [22]. Drug combinations that do not have ATC
codes for the corresponding drug components and com-
binations with none or unclear efficacy were discarded.
Finally, 194 effective drug combinations were obtained,
including 76 approved combinations, 64 clinical combi-
nations and 54 preclinical combinations. We then split
the combinations with more than two drug components
into combination pairs, resulting in 239 drug combina-
tion pairs. These drug combinations were used to con-
struct a drug cocktail network (Figure 1), where the
nodes represent drugs and the edges represent combina-
tions, respectively. In the drug cocktail network, the size
of each node denotes its degree and the width of each
edge denotes the therapeutic similarity (TS) between the
two drugs linked by the edge. The gray edge means that
there is no therapeutic similarity between the two drugs.
Human protein-protein interactions (PPIs) with high
confidence from STRING [30] were used to annotate
this drug cocktail network, which includes 169,603
interactions between 11,289 proteins after removing
pairs with low scores ( < 700).
Drug therapeutic similarity
The Anatomical Therapeutic Chemical (ATC) Classifica-
tion System, which includes 5 different hierarchical
levels, was used to classify drugs into different groups
according to the organ they acted on and the therapeu-
tic chemical characteristics. The k-th level drug thera-
peutic similarity (Sk) between two drugs is defined using
the ATC codes of these two drugs:
Sk(d1, d2) =
ATCk(d1) ∩ ATCk(d2)
ATCk(d1) ∪ ATCk(d2) (2)
where ATCk(d) denotes all the ATC codes at the k-th
level of drug d. Note that a drug has five levels of ATC
codes. A score, TS, is used to define the therapeutic







where n ranges from 1 to 5. In this study, n = 3 is
adopted considering that only a few drugs have the
same ATC codes at the 5th level.
Drug combination prediction
We assume that two drugs are more likely to be com-
bined if they share a large number of common drugs in
the drug cocktail network. For example, if two drugs d1
and d2 with respective n1 and n2 partners have m in
common in the drug cocktail network, there will be
three groups in the neighborhood of the two drugs, i.e.
(1) m drugs that are the neighbors of both drug d1 and
d2; (2) n1 - m partners that are the neighbors of drug d1
only; and (3) n2 - m partners are the neighbors of drug
d2 only [45]. Suppose that there are totally N drugs in
the drug combination network, then a p-value between
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If two drugs share more common drugs compared with
all of their neighbors, the p-value computed by equation
(4) will be closer to 0, which means they are more likely to
be combined. We use the equation (4) to compute the p-
values for all possible combinations and then rank the
values in ascending order. As drug pairs with lower p-
values are more likely to be combined, the prediction of
effective drug combinations can be made given a certain
p-value threshold. We term this framework that explores
the drug cocktail network and predicts possible drug com-
bination as DCPred (Drug Combination Predictor) and
assess its performance for inferring effective drug combi-
nations based on the curated drug combinations dataset.
Additional material
Additional file 1: The annotation of the neighbor drugs of DB00999
(Hydrochlorothiazide).
Additional file 2: The annotation of the neighbor drugs of DB00072
(Trastuzumab).
Additional file 3: The ranking of 1181 possible combinations by the
DCPred2 model.
Additional file 4: The ranking of 419 possible combinations by the
DCPred3 model.
Additional file 5: Prediction performance of the DCPred1 model at
varying thresholds, as measured by Sensitivity, Specificity and
Accuracy.
Additional file 6: Prediction performance of the DCPred2 model at
varying thresholds, as measured by Sensitivity, Specificity and
Accuracy.
Additional file 7: Prediction performance of the DCPred3 model at
varying thresholds, as measured by Sensitivity, Specificity and
Accuracy.
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